BMS Receives FDA’s Priority Review Acceptance of Lisocabtagene Maraleucel’s BLA for Patients with Relapsed or Refractory Large B-Cell Lymphoma

 BMS Receives FDA’s Priority Review Acceptance of Lisocabtagene Maraleucel’s BLA for Patients with Relapsed or Refractory Large B-Cell Lymphoma

BMS Receives FDA’s Priority Review Acceptance of Lisocabtagene Maraleucel’s BLA for Patients with Relapsed or Refractory Large B-Cell Lymphoma

Shots:

  • The BLA is based on P-I TRANSCEND NHL 001 study assessing Lisocabtagene Maraleucel (liso-cel) in 268 patients with r/r B-cell NHL including DLBCL, HGL, PMBCL and Grade 3B FL
  • The P-I TRANSCEND NHL 001 study is the largest study of CD19-directed CAR T cells supporting the BLA submission. Liso-cel has received FDA’s BT & RMAT designation for r/r large B-cell NHL and PRIME designation for r/r DLBCL
  • Liso-cel is CART-cell therapy targeting CD19 with a defined composition of CD8+ & CD4+ CAR T cells to treat r/r B-cell NHL prior treated with 2L+ therapies with its anticipated PDUFA date as Aug 17, 2020

Click here ­to­ read full press release/ article | Ref: BMS | Image: WSJ

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post